Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.
Researchers in Prof. Robert Malenka's laboratory have developed a light-activated animal system that could be used to identify compounds that treat certain psychiatric disorders.